Submission Request History

Navbar

Guidelines
Compendia & Templates
Education & Research
Patient Resources
Business & Policy
Global

Guidelines Treatment by Cancer Type Detection, Prevention, and Risk Reduction Supportive Care Specific Populations Guidelines for Patients Guidelines With Evidence Blocks Framework for Resource Stratification Harmonized Guidelines International Adaptations and Translations Guidelines Process Guidelines Panels and Disclosure Submissions, Licensing, and Permissions Recently Updated Guidelines

Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Anal Carcinoma Basal Cell Skin Cancer B-Cell Lymphomas Bladder Cancer Bone Cancer Breast Cancer Central Nervous System Cancers Cervical Cancer Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Chronic Myeloid Leukemia Colon Cancer Dermatofibrosarcoma Protuberans Esophageal and Esophagogastric Junction Cancers Gastric Cancer Gastrointestinal Stromal Tumors (GIST) Gestational Trophoblastic Neoplasia Hairy Cell Leukemia Head and Neck Cancers

Hepatobiliary Cancers Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma Kidney Cancer Malignant Pleural Mesothelioma Melanoma: Cutaneous Melanoma: Uveal Merkel Cell Carcinoma Multiple Myeloma Myelodysplastic Syndromes Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes Myeloproliferative Neoplasms Neuroendocrine and Adrenal Tumors Non-Small Cell Lung Cancer Occult Primary Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Pancreatic Adenocarcinoma Pediatric Acute Lymphoblastic Leukemia Pediatric Aggressive Mature B-Cell Lymphomas

Pediatric Hodgkin Lymphoma Penile Cancer Primary Cutaneous Lymphomas Prostate Cancer Rectal Cancer Small Bowel Adenocarcinoma Small Cell Lung Cancer Soft Tissue Sarcoma Squamous Cell Skin Cancer Systemic Light Chain Amyloidosis Systemic Mastocytosis T-Cell Lymphomas Testicular Cancer Thymomas and Thymic Carcinomas Thyroid Carcinoma Uterine Neoplasms Vulvar Cancer Waldenström Macroglobulinemia / Lymphoplasmacytic Lymphoma Wilms Tumor (Nephroblastoma)

Breast Cancer Risk Reduction Breast Cancer Screening and Diagnosis Colorectal Cancer Screening

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Genetic/Familial High-Risk Assessment: Colorectal Lung Cancer Screening

Prostate Cancer Early Detection

Adult Cancer Pain Antiemesis Cancer-Associated Venous Thromboembolic Disease Cancer-Related Fatigue

Distress Management Hematopoietic Cell Transplantation Hematopoietic Growth Factors Management of Immunotherapy-Related Toxicities

Palliative Care Prevention and Treatment of Cancer-Related Infections Smoking Cessation Survivorship

Adolescent and Young Adult (AYA) Oncology

Cancer in People with HIV

Older Adult Oncology

Acute Lymphoblastic Leukemia (adult) Acute Lymphoblastic Leukemia (pediatric) Acute Myeloid Leukemia Adolescents and Young Adults with Cancer Anal Cancer Anemia and Neutropenia - Low Red and White Blood Cell Counts B-Cell Lymphomas - Diffuse Large B-Cell Lymphoma B-Cell Lymphomas - Follicular Lymphoma B-Cell Lymphomas - Mantle Cell Lymphoma Bladder Cancer Bone Cancer Brain Cancer - Gliomas Breast Cancer - DCIS Breast Cancer Breast Cancer - Invasive Breast Cancer Breast Cancer - Metastatic Breast Cancer Central Nervous System Cancers - Primary Central Nervous System Lymphoma Chronic Lymphocytic Leukemia Chronic Myeloid Leukemia Colon Cancer

Distress Management - Distress During Cancer Care Esophageal Cancer Gallbladder and Bile Duct Cancers Head and Neck Cancers - Nasopharyngeal Cancer Head and Neck Cancers - Oral Cancers Head and Neck Cancers - Oropharyngeal Cancer Hodgkin Lymphoma Immunotherapy Side Effects: CAR T-Cell Therapy Immunotherapy Side Effects: Immune Checkpoint Inhibitors Kidney Cancer Liver Cancer Lung Cancer Screening Malignant Pleural Mesothelioma Melanoma Multiple Myeloma Mycosis Fungoides/Sézary Syndrome Myelodysplastic Syndromes Myeloproliferative Neoplasms Nausea and Vomiting

Neuroendocrine Tumors Non-Small Cell Lung Cancer - Early and Locally Advanced Non-Small Cell Lung Cancer - Metastatic Ovarian Cancer Pancreatic Cancer Primary Cutaneous Lymphomas Prostate Cancer: Advanced Stage Prostate Cancer: Early Stage Rectal Cancer Soft Tissue Sarcoma Squamous Cell Skin Cancer Stomach Cancer Survivorship Care for Cancer-Related Late and Long-Term Effects Survivorship Care for Healthy Living T-Cell Lymphomas - Peripheral T-Cell Lymphoma Thyroid Cancer Uterine Cancer Waldenström Macroglobulinemia

About Clinical Practice Guidelines Development and Update of Guidelines

Transparency Process Guidelines Panels Meeting Schedule

Disclosure Policies and Potential Conflicts of Interest

Guidelines Panels

Guideline Steering Committee

Licensing and Permissions Permissions Linking Permissions Distress Tool

Permissions Request Form Submission Request to the Guidelines Panels Submission Request History

Academic Publication Information

Compendia & Templates Compendia Chemotherapy Order Templates

NCCN Compendia Drugs and Biologics Compendium Biomarkers Compendium

Imaging AUC Compendium Radiation Therapy Compendium Subscribe to NCCN Compendium

Recognition Program

Browse by Cancer Type View Chemotherapy Order Templates User Guide

EHR Integration Chemotherapy Order Templates Committee

Subscribe to NCCN Templates Chemotherapy Order Templates Reviewer Acknowledgement

Education & Research Events and Programs Oncology Research Program JNCCN Publications

Calendar of Events Continuing Education

Annual Conference Annual Congress: Hematologic Malignancies

2021 Annual Congress: Hematologic Malignancies Sponsor and Exhibitor Prospectus

Oncology Research Program (ORP) Current Opportunities ORP Recent News ORP Grant History

Scientific Publications Clinical Trials Young Investigator Awards Informed Consent Language Database

Best Practices for Biorepositories Shared Resources Disclosure Policy

About JNCCN

Subscribe to JNCCN

JNCCN Email Updates

Business & Policy Business Policy and Advocacy Program

Corporate Council Academy Trends U.S. Surveys Trends Global Surveys Flash Updates

Order Free Pocket Guidelines and Guidelines for Patients Advertising Opportunities Research Tools: REMS Employer Toolkit Employer Resources

Virtual Reimbursement Resource Room and App Health Information Technology Licenses Embargo Policy Firewall Policy

Policy and Advocacy Program Oncology Policy Summits

Policy Priority: Improve and Facilitate Quality Cancer Care Policy Priority: Ensure Patient Accessibility

Policy Priority: Increase Use of Guidelines State Oncology Society Forum

Global Global Clinical Resources Global Support Opportunities Contact NCCN Global Global Events

NCCN Framework For Resource Stratification Harmonized Guidelines

International Adaptations and Translations Regions

Global Corporate Council Global Academy

Trends Global Surveys eBulletin Global Edition

Home
Guidelines
Submissions, Licensing, and Permissions
Submission Request History

Submission Request History

Treatment by Cancer Type
Detection, Prevention, and Risk Reduction
Supportive Care
Specific Populations
Guidelines for Patients
Guidelines With Evidence Blocks
Framework for Resource Stratification
Harmonized Guidelines
International Adaptations and Translations
Guidelines Process
Guidelines Panels and Disclosure
Submissions, Licensing, and Permissions
Recently Updated Guidelines

Acute Lymphoblastic Leukemia Panel

Blinatumomab Submitted by Amgen, Inc. on 10/03/2016
Multiplex PCR and high throughput sequencing (HTS) platform Submitted by Adaptive Biotechnologies on 12/09/2016
Ponatinib Submitted by ARIAD Pharmaceuticals Inc on 12/19/2016
Blinatumomab Submitted by Amgen, Inc. on 03/20/2017
Inotuzumab ozogamicin Submitted by Pfizer Inc. on 08/17/2017
Tisagenlecleucel Submitted by Novartis Pharmaceuticals Corporation on 08/31/2017
Blinatumomab Submitted by Amgen Inc. on 09/18/2017
Ibrutinib Submitted by Pharmacyclics, LLC on 09/29/2017
Defibrotide Sodium Submitted by Jazz Pharmaceuticals on 11/15/2017
Inotuzumab Submitted by Pfizer Inc. on 01/24/2018
Tisagenlecleucel Submitted by Novartis Pharmaceuticals Corporation on 03/29/2018
Hypercvad rituximab Submitted by Oregon Society of Medical Oncology on 08/08/2018
clonoSEQ® Submitted by Adaptive Biotechnologies Corporation on 09/13/2018
Glucarpidase Submitted by BTG International Inc. on 09/24/2018
clonoSEQ® Submitted by Adaptive Biotechnologies Corporation on 09/28/2018
Dasatinib Submitted by Bristol-Myers Squibb Company on 01/03/2019
Minimal (measurable) Residual Disease (MRD) Submitted by Adaptive Biotechnologies Corporation on 09/13/2019
clonoSEQ Submitted by Adaptive Biotechnologies on 10/27/2020
Blinatumomab Submitted by Amgen, Inc. on 12/10/2020
Asparaginase erwinia chrysanthemi (recombinant) Submitted by Jazz Pharmaceuticals on 07/02/2021

Acute Myeloid Leukemia Panel

Midostaurin Submitted by Novartis Pharmaceuticals Corporation on 05/02/2017
Next-Generation Sequencing (NGS) Submitted by Illumina Inc. on 06/26/2017
Isocitrate dehydrogenase-2 (IDH-2) testing Submitted by Celgene Corporation on 08/02/2017
Enasidenib Submitted by Celgene Corporation on 08/02/2017
Daunorubicin and Cytarabine Submitted by Jazz Pharmaceuticals on 08/07/2017
Gemtuzumab ozogamicin Submitted by Pfizer Inc. on 09/08/2017
Ibrutinib Submitted by Pharmacyclics LLC on 09/29/2017
Gemtuzumab ozogamicin Submitted by Pfizer Inc. on 10/03/2017
Gemtuzumab ozogamicin Submitted by Pfizer Inc. on 10/12/2017
Defibrotide Sodium Submitted by Jazz Pharmaceuticals on 11/15/2017
Gilteritinib Submitted by Astellas Pharma Inc. on 04/13/2018
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Submitted by Stemline Therapeutics, Inc on 04/20/2018
Ivosidenib Submitted by Agios Pharmaceuticals, Inc on 04/23/2018
Daunorubicin and Cytarabine Submitted by Jazz Pharmaceuticals on 04/27/2018
Venetoclax Submitted by AbbVie Inc. on 07/12/2018
Cytarabine and Daunorubicin Submitted by Jazz Pharmaceuticals on 11/05/2018
Venetoclax Submitted by AbbVie Inc. on 11/21/2018
Tagraxofusp Submitted by Stemline Therapeutics on 12/13/2018
Gilteritinib Submitted by Astellas Pharma Inc. on 01/18/2019
Liposomal Daunorubicin and Cytarabine Submitted by Jazz Pharmaceuticals on 03/07/2019
Daunorubicin and Cytarabine Submitted by Jazz Pharmaceuticals on 03/14/2019
Venetoclax Submitted by AbbVie Inc. on 03/21/2019
Ivosidenib Submitted by Agios Pharmaceuticals, Inc on 04/02/2019
Quizartinib Submitted by Daiichi Sankyo, Inc. on 04/19/2019
Gemtuzumab Ozogamicin Submitted by Pfizer Inc. on 04/22/2019
Tagraxofusp Submitted by Stemline Therapeutics, Inc. on 04/24/2019
Cytarabine and Daunorubicin Submitted by Jazz Pharmaceuticals on 04/26/2019
Gilterltinib Submitted by Astellas Pharma Inc. on 06/05/2019
Comprehensive genomic profiling Submitted by Foundation Medicine, Inc. on 05/01/2020
Venetoclax Submitted by AbbVie Inc. on 06/26/2020
CC-486 Submitted by Bristol-Myers Squibb Company on 07/07/2020
Venetoclax + HMAs Submitted by AbbVie Inc. on 08/14/2020
Azacitidine Submitted by Bristol-Myers Squibb Company on 09/01/2020

Adult Cancer Pain Panel

Magnetic resonance-guided focused ultrasound Submitted by Insightec on 09/12/2016
Interventional radiology Submitted by Society of Interventional Oncology on 09/16/2019
Polymerized Cross-linked Sucralfate Submitted by MMI Script Hub and Medical Supplies on 06/18/2020
Algorithm & Discussion Changes Submitted by Society of Interventional Oncology on 08/11/2020

Antiemesis Panel

Granisetron Submitted by Heron Therapeutics, Inc. on 08/10/2016
Fosaprepitant Dimeglumine Submitted by Merck & Co., Inc. on 10/17/2016
Carboplatin Submitted by Oncology Analytics, Inc. on 05/17/2017
Dronabinol Submitted by INSYS Therapeutics, Inc. on 08/11/2017
Granisetron Submitted by Heron Therapeutics, Inc. on 09/06/2017
Rolapitant Submitted by TESARO, Inc. on 10/20/2017
Aprepitant Submitted by Heron Therapeutics, Inc. on 11/15/2017
Fosnetupitant and Palonosetron Submitted by Helsinn Healthcare SA on 05/18/2018
Lenvatinib Submitted by Eisai Inc. on 04/21/2020

B-Cell Lymphomas Panel

Vitamin D-25OH and bone mineral density testing Submitted by Aurora Health Care on 04/07/2017
Pembrolizumab Submitted by Merck & Co., Inc. on 05/11/2017
Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2017
Rituximab and hyaluronidase Submitted by Genentech, Inc. on 06/23/2017
Ibrutinib Submitted by Pharmacyclics LLC on 08/02/2017
Ibrutinib Submitted by Pharmacyclics LLC on 08/02/2017
Copanlisib Submitted by Bayer Healthcare Pharmaceuticals on 09/15/2017
Obinituzumab Submitted by Genentech, Inc. on 10/11/2017
Copanlisib modification Submitted by Bayer Healthcare Pharmaceuticals on 10/18/2017
Copanlisib Submitted by Bayer Healthcare Pharmaceuticals on 10/18/2017
Axicabtagene ciloleucel Submitted by Kite on 10/20/2017
Acalabrutinib Submitted by AstraZeneca on 11/01/2017
Defibrotide Submitted by Jazz Pharmaceuticals on 11/27/2017
Ibrutinib Submitted by Pharmacyclics LLC on 12/21/2017
Tisagenlecleucel Submitted by Novartis Pharmaceuticals Corporation on 05/02/2018
Lenalidomide + Rituximab Submitted by Celgene Corporation on 06/03/2018
Next-generation sequencing Submitted by Adaptive Biotechnologies on 07/18/2018
Lenalidomide + Rituximab Submitted by Celgene Corporation on 08/07/2018
Duvelisib Submitted by Verastem, Inc. on 09/25/2018
Lenalidomide + Rituximab Submitted by Celgene Corporation on 12/03/2018
Obinutuzumab + Lenalidomide Submitted by Genentech, Inc. on 12/06/2018
Lenalidomide + Rituximab Submitted by Celgene Corporation on 03/22/2019
Lenalidomide + Rituximab Submitted by Celgene Corporation on 05/28/2019
Polatuzumab vedotin Submitted by Genentech, Inc. on 06/10/2019
Siltuximab Submitted by EUSA Pharma, Inc. on 08/01/2019
Obinutuzumab + Lenalidomide Submitted by Genentech, Inc. on 08/01/2019
Nivolumab Submitted by Bristol-Myers Squibb Company on 08/09/2019
Zanubrutinib Submitted by BeiGene, Ltd. on 11/14/2019
Polatuzumab Vedotin Submitted by Genentech, Inc. on 12/17/2019
Ibrutinib Submitted by Pharmacyclics LLC on 12/19/2019
2 Gy x 2 fractions Submitted by Oncology Analytics, Inc. on 02/08/2020
Zanubrutinib Submitted by BeiGene, Ltd. on 04/17/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Tazemetostat Submitted by Epizyme Inc. on 06/18/2020
Selinexor Submitted by Karyopharm Therapeutics on 06/23/2020
Brexucabtagene Autoleucel Submitted by Kite on 07/24/2020
Tafasitamab-cxix in combo with Lenalidomide Submitted by MorphoSys US Inc. and Incyte Corporation on 08/03/2020
NGS clarification Submitted by Adaptive Biotechnologies Corporation on 09/01/2020
Siltuximab Submitted by Castleman Disease Collaborative Network (CDCN) on 09/08/2020
Axicabtagene ciloleucel Submitted by Kite on 09/18/2020
Axicabtagene ciloleucel Submitted by Kite on 12/08/2020
Lisocabtagene maraleucel Submitted by Bristol Myers Squibb on 02/08/2021
Umbralisib Submitted by TG Therapeutics, Inc on 02/09/2021
Umbralisib Submitted by TG Therapeutics, Inc on 02/10/2021
Loncastuximab tesirine‐lpyl Submitted by ADC Therapeutics on 04/23/2021

Bladder/Penile Cancers Panel

Atezolizumab Submitted by Genentech, Inc. on 08/21/2016
Nivolumab Submitted by Bristol-Myers Squibb Company on 10/10/2016
Nivolumab Submitted by Bristol-Myers Squibb Company on 02/03/2017
Pembrolizumab Submitted by Merck & Co., Inc. on 02/20/2017
Atezolizumab Submitted by Genentech, Inc. on 04/17/2017
Durvalumab Submitted by AstraZeneca on 05/02/2017
Avelumab Submitted by EMD Serono, Inc. on 05/09/2017
Pembrolizumab Submitted by Merck & Co., Inc. on 05/19/2017
Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2017
Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2017
Csbladder Assays Submitted by Pacific Edge Diagnostics USA, Ltd. on 07/31/2017
Atezolizumab Submitted by Genentech, Inc. on 08/23/2017
Nivolumab Submitted by Bristol-Myers Squibb Company on 03/06/2018
Atezolizumab Submitted by Genentech, Inc. on 06/20/2018
Cystoscopy Submitted by Photocure, Inc. on 08/07/2018
Molecular testing Submitted by Foundation Medicine, Inc. on 08/23/2018
Cxbladder Monitor Assay Submitted by Pacific Edge Diagnostics USA, Ltd. on 08/31/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 10/23/2018
Erdafitinib Submitted by Janssen Scientific Affairs, LLC on 04/15/2019
Atezolizumab Submitted by Genentech, Inc. on 06/18/2019
Nivolumab Submitted by Bristol-Myers Squibb Company on 07/09/2019
Erdafitinib Submitted by Janssen Scientific Affairs, LLC on 07/30/2019
Genetic Alterations Submitted by Foundation Medicine, Inc. on 08/26/2019
Atezolizumab Submitted by Genentech, Inc. on 08/27/2019
Enfortumab vedotin Submitted by Seattle Genetics, Inc. on 12/06/2019
Pembrolizumab Submitted by Merck & Co., Inc. on 01/08/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/30/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
Avelumab Submitted by Pfizer Inc./EMD Serono, Inc. on 06/30/2020
Patient Advocate Recommendations Submitted by Bladder Cancer Advocacy Network (BCAN) on 07/27/2020
Urothelial tumor markers Submitted by Pacific Edge Diagnostics USA, Ltd. on 08/13/2020
Comprehensive genomic profiling Submitted by Foundation Medicine, Inc. on 08/28/2020
Avelumab Submitted by Pfizer Inc./EMD Serono, Inc. on 09/18/2020
Enfortumab vedotin Submitted by Seagen Inc./Astellas Pharma Global Development, Inc. on 02/16/2021
Atezolizumab Submitted by Genentech, Inc. on 03/08/2021
Sacituzumab govitecan-hziy Submitted by Gilead Sciences, Inc. on 04/15/2021
Nivolumab Submitted by Bristol Myers Squibb on 06/03/2021
Enfortumab vedotin-ejfv Submitted by Seagen Inc. on 07/13/2021

Bone Cancer Panel

Pembrolizumab Submitted by Merck & Co. on 05/31/2017
Cabozantinib Submitted by Exelixis, Inc. on 04/12/2019
Entrectinib Submitted by Genentech, Inc. on 08/15/2019
Glucarpidase Submitted by BTG International Inc. on 12/18/2019
Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020
Ivosidenib Submitted by Agios Pharmaceuticals, Inc. on 03/30/2020
Cabozantinib Submitted by Exelixis, Inc. on 04/15/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/24/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 09/18/2020
Comprehensive genomic profiling (CGP) Submitted by Foundation Medicine, Inc. on 04/15/2021
Comprehensive genomic profiling (CGP) Submitted by Illumina Inc. on 04/27/2021

Breast Cancer Panel

Albumin-bound paclitaxel Submitted by Celgene Corporation on 01/13/2017
Ribociclib Submitted by Novartis Pharmaceuticals Corporation on 03/13/2017
Palbociclib Submitted by Pfizer Inc. on 04/03/2017
Recommend clarification on the locoregional recurrence section Submitted by American Society for Radiation Oncology (ASTRO) on 05/25/2017
70 gene MammaPrint assay Submitted by Agendia, Inc. on 05/26/2017
Pembrolizumab Submitted by Merck & Co. on 05/31/2017
Pertuzumab/Trastuzumab Submitted by Genentech, Inc. on 06/12/2017
Prosigna® Breast Cancer Gene Signature Assay Submitted by NanoString Technologies on 06/23/2017
Docetaxel Submitted by Hadassah-Hebrew University Medical Center on 06/30/2017
Goserelin Submitted by TerSera Therapeutics on 07/03/2017
70 gene MammaPrint assay Submitted by Agendia, Inc. on 07/03/2017
Bioimpedance spectroscopy Submitted by ImpediMed, Inc. on 07/10/2017
Oncotype DX® Breast DCIS Score™ assay Submitted by Genomic Health, Inc. on 07/10/2017
Oncotype DX® Breast Recurrence Score™ (RS) assay Submitted by Genomic Health, Inc. on 07/10/2017
Oncotype DX® Breast Recurrence Score™ (RS) assay Submitted by Genomic Health, Inc. on 07/10/2017
12-gene recurrence test Submitted by Myriad Genetic Laboratories, Inc. on 07/11/2017
Comprehensive genomic profiling (CGP) assays Submitted by Foundation Medicine, Inc. on 07/14/2017
Neratinib Submitted by Puma Biotechnology, Inc. on 07/17/2017
Everolimus Submitted by Novartis Pharmaceuticals Corporation on 07/19/2017
Fulvestrant Submitted by AstraZeneca on 08/28/2017
Abemaciclib Submitted by Eli Lilly and Company on 09/28/2017
Olaparib Submitted by AstraZeneca on 11/14/2017
Fulvestrant Submitted by AstraZeneca on 11/15/2017
Ribociclib Submitted by Novartis Pharmaceuticals Corporation on 12/06/2017
Neratinib Submitted by Puma Biotechnology, Inc. on 12/28/2017
Comprehensive genetic testing Submitted by Illumina Inc. on 02/08/2018
Abemaciclib Submitted by Eli Lilly and Company on 02/26/2018
Tamoxifen Submitted by Sanford Health Pharmacogenomics Committee on 02/28/2018
Paxman Scalp Cooling System Submitted by Paxman Coolers Limited on 06/12/2018
Ribociclib + Fulvestrant Submitted by AstraZeneca on 06/28/2018
Ribociclib + Fulvestrant Submitted by Novartis Pharmaceuticals Corporation on 06/29/2018
Oncotype DX® Breast DCIS Score™ assay Submitted by Genomic Health, Inc. on 07/03/2018
Oncotype DX Breast Recurrence Score® (RS) assay Submitted by Genomic Health, Inc. on 07/03/2018
Oncotype DX Breast Recurrence Score® (RS) assay Submitted by Genomic Health, Inc. on 07/03/2018
Oncotype DX Breast Recurrence Score® (RS) assay Submitted by Genomic Health, Inc. on 07/03/2018
Next-generation sequencing (NGS) Submitted by Foundation Medicine, Inc. on 07/03/2018
Radiofrequency spectroscopy Submitted by Dune Medical, Inc. on 07/05/2018
EndoPredict Submitted by Myriad Genetic Laboratories, Inc. on 07/06/2018
EndoPredict Submitted by Myriad Genetic Laboratories, Inc. on 07/06/2018
Talazoparib Submitted by Pfizer Inc. on 10/16/2018
Atezolizumab Submitted by Genentech, Inc. on 10/20/2018
Ado-trastuzumab emtansine Submitted by Genentech, Inc. on 12/05/2018
Neratinib Submitted by Puma Biotechnology, Inc. on 12/21/2018
Genetic Testing Guidelines Submitted by Targeted Medical Education (TME) on 02/18/2019
Trastuzumab and Hyaluronidase-oysk Submitted by Genentech, Inc. on 02/28/2019
Atezolizumab Submitted by Genentech, Inc. on 03/08/2019
Alpelisib Submitted by Novartis Pharmaceuticals Corporation on 05/24/2019
Larotrectinib Submitted by Bayer Healthcare Pharmaceuticals on 05/28/2019
Ribociclib Submitted by Novartis Pharmaceuticals Corporation on 06/06/2019
Neratinib Submitted by Puma Biotechnology, Inc. on 06/10/2019
Neratinib + Capecitabine Submitted by Puma Biotechnology, Inc. on 06/10/2019
Locoregional therapies Submitted by Society of Interventional Oncology on 06/14/2019
Trastuzumab-dkst Submitted by Mylan N.V. on 06/26/2019
Oncotype DX® Breast DCIS Score™ assay Submitted by Genomic Health, Inc. on 07/15/2019
Trastuzumab-anns Submitted by Amgen Inc. on 07/19/2019
Subclinical Lymphedema Submitted by Vanderbilt University School of Nursing on 07/19/2019
EndoPredict Submitted by Myriad Genetic Laboratories, Inc. on 07/23/2019
EndoPredict Submitted by Myriad Genetic Laboratories, Inc. on 07/23/2019
Genomic Assays Submitted by Myriad Genetic Laboratories, Inc. on 07/23/2019
Trastuzumab-dttb Submitted by Samsung Bioepis Co., Ltd. on 07/24/2019
Atezolizumab, Pertuzumab, Ado-trastuzumab Emtansine Submitted by Genentech, Inc. on 07/24/2019
Next-Generation Sequencing Assays Submitted by Foundation Medicine, Inc. on 07/24/2019
Breast Cancer Index (BCI) Submitted by Biotheranostics, Inc. on 07/25/2019
Denosumab Submitted by My Style Matters on 07/25/2019
Ixabepilone + Capecitabine Submitted by R-Pharm US on 07/30/2019
Entrectinib Submitted by Genentech, Inc. on 08/15/2019
Pembrolizumab Submitted by Merck & Co., Inc. on 09/29/2019
Abemaciclib Submitted by Eli Lilly and Company on 10/29/2019
Tucatinib Submitted by Seattle Genetics Inc. on 12/24/2019
Fam-trastuzumab deruxtecan-nxki Submitted by Daiichi-Sankyo, Inc., and AstraZeneca Pharmaceuticals LP on 01/02/2020
EndoPredict Submitted by Myriad Genetics Laboratories Inc. on 01/27/2020
Estrogen receptor alpha-36 testing Submitted by Christina Rosati on 02/25/2020
Neratinib + capecitabine Submitted by Puma Biotechnology, Inc. on 02/27/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 03/18/2020
Tucatinib Submitted by Seattle Genetics, Inc. on 04/17/2020
Sacituzumab govitecan-hziy Submitted by Immunomedics, Inc. on 04/22/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Alpelisib + fulvestrant Submitted by Novartis Pharmaceuticals Corporation on 05/12/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 05/29/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
TMB testing Submitted by Foundation Medicine, Inc. on 06/22/2020
Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Submitted by Genentech, Inc. on 06/29/2020
Ado-trastuzumab emtansine Submitted by Linda W. Wilson, MD on 07/08/2020
Radiation Therapy Submitted by American Society for Radiation Oncology (ASTRO) on 07/20/2020
21-Gene RT-PCR assay Submitted by Exact Sciences on 07/28/2020
FES PET Submitted by Zionexa on 07/29/2020
PET/CT Submitted by Society of Interventional Radiology on 07/30/2020
EndoPredict Submitted by Myriad Genetics Laboratories, Inc. on 08/01/2020
PET/CT Submitted by MD Anderson Cancer Center on 08/04/2020
Pertuzumab + ado-trastuzumab emtansine Submitted by Genentech Inc. on 08/05/2020
Breast Cancer Index Submitted by Biotheranostics Inc. on 08/05/2020
Breast Cancer Index Submitted by Biotheranostics Inc. on 08/05/2020
L-Dex Submitted by ImpediMed Limited on 08/05/2020
Neratinib Submitted by Puma Biotechnology on 08/05/2020
NGS assay Submitted by Guardant Health on 08/06/2020
NGS assay Submitted by Foundation Medicine Inc. on 08/06/2020
TMB testing Submitted by Foundation Medicine Inc. on 09/15/2020
Neratinib Submitted by Puma Biotechnology on 10/05/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 11/16/2020
Atezolizumab + albumin-bound paclitaxel Submitted by Genentech Inc. on 12/02/2020
Olaparib Submitted by AstraZeneca on 06/09/2021

Breast Cancer Risk Reduction Panel

riskScore™ Submitted by Myriad Genetic Laboratories, Inc. on 07/06/2020
BBDRisk Dx® MAAA (Multianalyte Assays with Algorithmic Analysis) Submitted by Silbiotech on 07/10/2020

Breast Cancer Screening and Diagnosis Panel

Digital Breast Tomosynthesis Submitted by Hologic, Inc. on 10/28/2018

Cancer- and Chemotherapy-Induced Anemia Panel

ESA REMS and ESA APPRISE Oncology Programs Submitted by Amgen, Inc. on 04/14/2017

Cancer in People with HIV/Kaposi Sarcoma Panel

Pomalidomide Submitted by Bristol-Myers Squibb Company on 05/19/2020

Cancer-Associated Venous Thromboembolic Disease Panel

Apixaban Submitted by Bristol-Myers Squibb Company on 12/21/2018
Apixaban Submitted by Bristol-Myers Squibb Company on 11/06/2019
Apixaban Submitted by Bristol-Myers Squibb Company on 04/06/2020
Andexanet alfa Submitted by Bristol Myers Squibb on 06/25/2020
Acute DVT Submitted by Society of Interventional Oncology on 10/27/2020

Central Nervous System Cancers Panel

Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/05/2017
Defibrotide Sodium Submitted by Jazz Pharmaceuticals on 11/27/2017
Osimertinib Submitted by AstraZeneca Pharmaceuticals LP on 04/19/2018
Bevacizumab Submitted by Munson Medical Oncology on 05/02/2018
Glucarpidase Submitted by BTG International Inc. on 09/13/2018
Regorafenib Submitted by Bayer Healthcare Pharmaceuticals on 12/10/2018
Osimertinib Submitted by AstraZeneca on 01/17/2019
Neratinib + Capecitabine Submitted by Puma Biotechnology, Inc. on 04/05/2019
Vitrakvi Submitted by Bayer Healthcare Pharmaceuticals on 05/28/2019
Neratinib + Capecitabine Submitted by Puma Biotechnology, Inc. on 06/10/2019
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/18/2019
Bevacizumab-awwb Submitted by Amgen on 07/19/2019
Entrectinib Submitted by Genentech, Inc. on 08/15/2019
Osimertinib Submitted by AstraZeneca on 04/14/2020
Tucatinib Submitted by Seattle Genetics, Inc. on 04/17/2020
Selumetinib Submitted by AstraZeneca on 05/04/2020
Selumetinib Submitted by AstraZeneca on 05/04/2020
Tucatinib Submitted by Seattle Genetics, Inc. on 05/29/2020
Aminolevulinic acid hydrochloride Submitted by NX Development Corp on 06/02/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
Nivolumab + Ipilimumab Submitted by Bristol Myers Squibb on 06/23/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/24/2020
Laser Interstitial Thermal Therapy (LITT) Submitted by Washington University School of Medicine; Department of Neurological Surgery on 08/28/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 09/18/2020
Capmatinib Submitted by Novartis Pharmaceuticals Corporation on 12/11/2020

Cervical/Uterine Cancers Panel

Olaratumab in combination with doxorubicin Submitted by Eli-Lilly and Company on 03/22/2017
Genetic counseling/testing for patients without MMR abnormalities Submitted by Myriad Genetic Laboratories, Inc. on 03/29/2017
Pembrolizumab for MSI-H/dMMR tumors for Cervical Cancer Submitted by Merck & Co. on 05/31/2017
Pembrolizumab for MSI-H/dMMR tumors for Uterine Neoplasms Submitted by Merck & Co. on 05/31/2017
Pembrolizumab for MSI-H/dMMR tumors for Vulvar Cancer Submitted by Merck & Co. on 05/31/2017
Trastuzumab Submitted by Genentech, Inc. on 04/26/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 06/12/2018
Radiation Therapy Submitted by American Society for Radiation Oncology on 04/30/2019
PCR-based Microsatellite Instability (MSI) assays Submitted by Promega Corporation on 05/17/2019
Lenvatinib in combination with pembrolizumab Submitted by Eisai Inc. on 06/28/2019
Bevacizumab-awwwb Submitted by Amgen on 07/19/2019
Entrectinib and appropriate NTRK gene fusion testing Submitted by Genentech on 08/15/2019
Entrectinib Submitted by Genentech, Inc. on 08/15/2019
Nivolumab Submitted by Bristol-Myers Squibb on 10/17/2019
Nivolumab for Vulvar Cancer Submitted by Bristol-Myers Squibb on 10/17/2019
Nivolumab for Uterine Neoplasms Submitted by Bristol-Myers Squibb on 12/04/2019
Pembrolizumab for Uterine Neoplasms Submitted by Merck & Co., Inc. on 03/19/2020
Pembrolizumab Submitted by Merck & Co, Inc. on 03/20/2020
Pembrolizumab for Vulvar Cancer Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Pembrolizumab dosing for Vulvar Cancer Submitted by Merck & Co., Inc. on 04/29/2020
Pembrolizumab dosing for Uterine Neoplasms Submitted by Merck & Co., Inc. on 04/29/2020
Systemic Therapy Table Headings for Uterine Neoplasms Submitted by GSK on 05/15/2020
Pembrolizumab for Cervical Cancer Submitted by Merck & Co., Inc. on 06/17/2020
Pembrolizumab for Uterine Neoplasms Submitted by Merck & Co., Inc. on 06/17/2020
Pembrolizumab for Vulvar Cancer Submitted by Merck & Co., Inc. on 06/17/2020
Pembrolizumab and TMB testing for Cervical Cancer Submitted by Foundation Medicine, Inc. on 06/22/2020
Pembrolizumab and TMB testing for Vulvar Cancer Submitted by Foundation Medicine, Inc. on 06/22/2020
Pembrolizumab and TMB testing for Uterine Neoplasms Submitted by Foundation Medicine, Inc. on 06/30/2020
Avelumab Submitted by EMD Serono, Inc. on 08/11/2020
Dostarlimab-gxly (Uterine Neoplasms) Submitted by GlaxoSmithKline on 04/22/2021

Chronic Myeloid Leukemia Panel

Bosutinib Submitted by Pfizer Inc. on 11/01/2017
Defibrotide Sodium Submitted by Jazz Pharmaceuticals on 11/17/2017
Dasatinib Submitted by Bristol-Myers Squibb Company on 12/10/2017
Bosutinib Submitted by Pfizer Inc. on 12/19/2017
Nilotinib Submitted by Novartis Pharmaceuticals Corporation on 01/18/2018
Next-generation sequencing Submitted by Illumina Inc. on 02/27/2018
Nilotinib Submitted by Novartis Pharmaceuticals Corporation on 03/22/2018
Nilotinib Submitted by Novartis Pharmaceuticals Corporation on 03/22/2018
Nilotinib Submitted by Novartis Pharmaceuticals Corporation on 05/02/2019
Ponatinib Submitted by Takeda Oncology on 10/21/2020

CLL/SLL/Hairy Cell Leukemia Panel

Ibrutinib Submitted by Pharmacyclics, LLC on 02/27/2017
Serum free light chain assays Submitted by Aurora Health Care on 04/07/2017
Rituximab/Hyaluronidase Submitted by Genentech, Inc. on 05/20/2017
Pembrolizumab Submitted by Merck & Co. on 05/31/2017
Ibrutinib Submitted by Pharmacyclics, LLC on 06/05/2017
Ibrutinib Submitted by Pharmacyclics LLC on 08/02/2017
Obinutuzumab Submitted by Genentech, Inc. on 08/10/2017
Defibrotide sodium Submitted by Jazz Pharmaceuticals on 11/27/2017
Venetoclax Submitted by AbbVie Inc. on 12/13/2017
Ibrutinib Submitted by Pharmacyclics LLC on 12/21/2017
TP53 genetic sequencing Submitted by Illumina Inc. on 04/06/2018
Ibrutinib Submitted by Pharmacyclics LLC on 06/20/2018
Venetoclax Submitted by AbbVie Inc. on 06/21/2018
Moxetumomab pasudotox-tdfk Submitted by AstraZeneca on 09/15/2018
Duvelisib Submitted by Verastem, Inc. on 09/25/2018
Ibrutinib Submitted by Pharmacyclics LLC on 12/20/2018
Acalabrutinib Submitted by AstraZeneca on 12/21/2018
clonoSEQ assay Submitted by Adaptive Biotechnologies Corporation on 05/13/2019
Venetoclax Submitted by AbbVie Inc. on 05/16/2019
Venetoclax + Obinutuzumab Submitted by AbbVie Inc. on 06/05/2019
Venetoclax + Rituximab Submitted by AbbVie Inc. on 06/05/2019
Acalabrutinib Submitted by AstraZeneca on 06/26/2019
Ibrutinib Submitted by Pharmacyclics LLC on 06/28/2019
Acalabrutinib Submitted by AstraZeneca on 07/09/2019
Rituximab-abbs Submitted by Teva Pharmaceuticals USA, Inc. on 09/23/2019
Acalabrutinib Submitted by AstraZeneca/Medical Affairs on 11/21/2019
Zanubrutinib Submitted by BeiGene, Ltd. on 12/17/2019
Moxetumomab pasudotox-tdfk Submitted by Innate Pharma, Inc. on 05/08/2020
clonoSEQ Submitted by Adaptive Biotechnologies Corporation on 05/12/2020
Ibrutinib Submitted by Pharmacyclics LLC on 05/15/2020
Zanubrutinib Submitted by BeiGene, Ltd. on 05/15/2020
Acalabrutinib Submitted by AstraZeneca on 05/23/2020
Venetoclax + Obinutuzumab Submitted by AbbVie Inc. on 06/02/2020
Zanubrutinib Submitted by BeiGene, Ltd. on 08/03/2020
Venetoclax + Obinutuzumab Submitted by AbbVie Inc. on 09/11/2020

Colon/Rectal/Anal Cancers Panel

EGFR tumor location Submitted by Amgen, Inc. on 12/19/2016
Panitumumab Submitted by Amgen, Inc. on 01/30/2017
Vemurafenib Submitted by Genentech, Inc. on 02/22/2017
Fluoropyrimidine Submitted by Kenneth E. Surprenant on 04/24/2017
Ziv-aflibercept Submitted by Sanofi Genzyme on 05/15/2017
Nivolumab Submitted by Bristol-Myers Squibb Company on 05/22/2017
Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2017
Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2017
Nivolumab Submitted by Bristol-Myers Squibb Company on 06/04/2017
Vemurafenib Submitted by Genentech, Inc. on 07/21/2017
Nivolumab Submitted by Bristol-Myers Squibb Company on 08/01/2017
Oncotype DX® Colon Recurrence Score® assay Submitted by Genomic Health, Inc. on 08/07/2017
CGP assays Submitted by Foundation Medicine, Inc. on 08/10/2017
Yttrium-90 Submitted by Sirtex Medical Limited on 08/16/2017
RAS molecular testing Submitted by Illumina Inc. on 01/03/2018
RAS molecular testing Submitted by Illumina Inc. on 01/03/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 01/22/2018
Regorafenib Submitted by Bayer Healthcare Pharmaceuticals on 01/26/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 03/06/2018
Trastuzumab + Pertuzumab Submitted by Genentech, Inc. on 05/11/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 07/11/2018
Immunoscore testing Submitted by HalioDx on 07/24/2018
Radiation Therapy Submitted by American Society for Radiation Oncology (ASTRO) on 07/31/2018
Yttrium 90 Submitted by Sirtex Medical Inc on 08/02/2018
Atezolizumab Submitted by Genentech, Inc. on 08/07/2018
Fluoropyrimidines Submitted by Gabriel A. Brooks, MD, MPH & Ken Surprenant on 08/08/2018
Comprehensive Genomic Profiling (CGP) assay Submitted by Foundation Medicine, Inc. on 08/09/2018
Yttrium 90 Submitted by Sirtex Medical Inc on 08/10/2018
Vitrakvi Submitted by Bayer Healthcare Pharmaceuticals on 12/10/2018
Encorafenib + Binimetinib + Cetuximab Submitted by Array BioPharma Inc. on 02/26/2019
Nivolumab Submitted by Bristol-Myers Squibb Company on 04/19/2019
Nivolumab Submitted by Bristol-Myers Squibb Company on 05/03/2019
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/03/2019
Transanal full thickness local excision Submitted by Ascension St. John Hospital on 06/04/2019
Encorafenib + Binimetinib + Cetuximab Submitted by Array BioPharma Inc. on 07/16/2019
Bevacizumab-awwb Submitted by Amgen on 07/19/2019
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 07/24/2019
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 07/24/2019
Levoleucovorin Submitted by Acrotech Biopharma LLC on 07/25/2019
DPYD genetic testing Submitted by University of Michigan College of Pharmacy on 07/29/2019
MSI Assays Submitted by Promega Corporation on 07/29/2019
Regorafenib + Nivolumab Submitted by Bayer Healthcare Pharmaceuticals on 07/30/2019
yttrium-90 Submitted by Society of Interventional Oncology on 08/08/2019
Entrectinib Submitted by Genentech, Inc. on 08/15/2019
Comprehensive genomic profiling (CGP) Submitted by Guardant Health, Inc. on 01/30/2020
Pembrolizumab for Anal Carcinoma Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab for Small Bowel Adenocarcinoma Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Pembrolizumab for Rectal Cancer Submitted by Merck & Co., Inc. on 06/01/2020
Pembrolizumab for Colon Cancer Submitted by Merck & Co., Inc. on 06/01/2020
Nivolumab + Ipilimumab Submitted by Bristol Myers Squibb Company on 06/01/2020
Trifluridine and Tipiracil Submitted by Taiho Oncology, Inc. on 06/10/2020
Pembrolizumab for Small Bowel Adenocarcinoma Submitted by Merck & Co., Inc. on 06/17/2020
Tumor Mutational Burden (TMB) for Colon Cancer Submitted by Foundation Medicine, Inc. on 06/22/2020
Tumor Mutational Burden (TMB) for Rectal Cancer Submitted by Foundation Medicine, Inc. on 06/22/2020
Immunoscore assay Submitted by HalioDx on 06/25/2020
Pembrolizumab for Colon Cancer Submitted by Merck & Co., Inc. on 06/30/2020
Pembrolizumab for Rectal Cancer Submitted by Merck & Co., Inc. on 06/30/2020
Fam-trastuzumab deruxtecan-nxki Submitted by Daiichi Sankyo, Inc. and AstraZeneca Pharmaceuticals LP on 07/09/2020
Post-surgical tumor-informed ctDNA for Colon Cancer Submitted by Natera, Inc. on 07/13/2020
Tumor-informed ctDNA for Colon Cancer Submitted by Natera, Inc. on 07/13/2020
Post-surgical tumor-informed ctDNA for Rectal Cancer Submitted by Natera, Inc. on 07/13/2020
Tumor-informed ctDNA for Rectal Cancer Submitted by Natera, Inc. on 07/13/2020
yttrium-90 Submitted by Society of Interventional Oncology on 07/14/2020
Next-generation sequencing (NGS) Submitted by Guardant Health, Inc. on 07/20/2020
Circulating Tumor DNA (ctDNA) Submitted by Colorectal Cancer Alliance on 08/10/2020
Tumor Mutational Burden (TMB) for Small Bowel Adenocarcinoma Submitted by Foundation Medicine, Inc. on 09/16/2020
Tumor Mutational Burden (TMB) for Colon Cancer Submitted by Foundation Medicine, Inc. on 09/18/2020
Tumor Mutational Burden (TMB) for Rectal Cancer Submitted by Foundation Medicine, Inc. on 09/18/2020

Colorectal Cancer Screening Panel

Average-risk CRC screening Submitted by Exact Sciences Corporation on 10/29/2018
Epi proColon Submitted by Epigenomics AG on 12/05/2019
Epi proColon Submitted by Epigenomics Inc. on 09/28/2020
FIT-DNA-based testing Submitted by Exact Sciences Corporation on 10/13/2020

Distress Management Panel

PHQ-2 and PHQ-9 Questionnaire Submitted by Wake Forest School of Medicine on 12/21/2016

Esophageal/Gastric Cancers Panel

Uridine triacetate Submitted by Wellstat Therapeutics Corporation on 08/17/2016
High‐Risk Syndromes Submitted by Myriad Genetic Laboratories, Inc. on 08/17/2016
Pembrolizumab for Gastric Cancer Submitted by Merck & Co. on 05/31/2017
Pembrolizumab for Esophageal Cancer Submitted by Merck & Co. on 05/31/2017
Pertuzumab in combination with trastuzumab and chemotherapy Submitted by Genentech, Inc. on 09/15/2017
Pertuzumab in combination with trastuzumab and chemotherapy for HER2 positive tumors for Esophageal and Esophagogastric Cancer Submitted by Genentech, Inc. on 09/15/2017
Nivolumab for Gastric Cancer Submitted by Bristol-Myers Squibb on 09/21/2017
Nivolumab for Esophageal and Esophagogastric Cancer Submitted by Bristol-Myers Squibb on 09/21/2017
Pembrolizumab for PD-L1 tumors for Gastric Cancer Submitted by Merck & Co. on 09/29/2017
Pembrolizumab for PD-L1 tumors for Esophageal and Esophagogastric Cancer Submitted by Merck & Co. on 09/29/2017
Trifluridine/Tipiracil Submitted by Taiho Oncology, Inc. on 07/13/2018
Trastuzumab Submitted by Eli Lilly and Company on 07/17/2018
Principles of Pathologic Review Submitted by Foundation Medicine, Inc. on 09/11/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 09/28/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 09/28/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 01/29/2019
Trastuzumab-dkst Submitted by Mylan N.V. on 06/26/2019
Trastuzumab-anns Submitted by Amgen on 07/19/2019
Scalp cooling system for Esophageal and Gastric Submitted by Paxman Coolers Limited on 07/26/2019
Regorafenib plus nivolumab for Gastric Cancer Submitted by Bayer Healthcare Pharmaceuticals on 07/30/2019
Trastuzumab-dttb Submitted by Samsung Bioepis Co., Ltd on 08/02/2019
Entrectinib and appropriate NTRK gene fusion testing Submitted by Genentech, Inc. on 08/15/2019
Comprehensive genetic profiling Submitted by Foundation Medicine, Inc. on 09/05/2019
Wide area transepithelial sampling for Esophageal Cancer Submitted by CDx Diagnostics, Inc on 09/06/2019
Pembrolizumab Submitted by Oncology Analytics on 09/18/2019
PCR-based microsatellite instability assays for Esophageal and Gastric Cancer Submitted by Promega Corporation on 09/23/2019
Nivolumab for Esophageal Cancer Submitted by Bristol-Myers Squibb on 09/30/2019
Plasma-based comprehensive genomic profiling for Esophageal Cancer Submitted by Guardant Health on 01/30/2020
Pembrolizumab for Gastric Cancer Submitted by Merck & Co., Inc. on 03/12/2020
Pembrolizumab for Esophageal Cancer Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab for Esophageal and Esophagogastric Cancer Submitted by Merck & Co., Inc on 04/29/2020
Pembrolizumab for Gastric Cancer Submitted by Merck & Co., Inc on 04/29/2020
Fam-trastuzumab deruxtecan-nxki Submitted by Daiichi-Sankyo, Inc. on 06/04/2020
Fam-trastuzumab deruxtecan-nxki (Esophageal and Gastric Cancers) Submitted by Daiichi-Sankyo and Astrazeneca Pharmaceuticals on 06/04/2020
Nivolumab for Esophageal squamous cell carcinoma Submitted by Bristol Myers Squibb on 06/11/2020
Pembrolizumab for TMB-H for Esophageal Cancer Submitted by Merck & Co., Inc. on 06/17/2020
Pembrolizumab for TMB for Gastric Cancer Submitted by Merck & Co., Inc. on 06/17/2020
Tumor mutational burden (TMB) testing for Esophageal Cancer Submitted by Foundation Medicine, Inc. on 06/22/2020
Tumor mutational burden (TMB) testing for Gastric Cancer Submitted by Foundation Medicine, Inc. on 06/22/2020
Comprehensive genomic profiling for Esophageal Cancer Submitted by Foundation Medicine, Inc. on 08/26/2020
Tumor mutational burden (TMB) testing for Gastric Cancer Submitted by Foundation Medicine, Inc. on 08/26/2020
Plasma-based comprehensive genomic profiling Submitted by Guardant Health on 08/26/2020
Pembrolizumab with chemotherapy for Esophageal Cancer Submitted by Merck & Co., Inc. on 09/21/2020
Nivolumab for Esophageal Cancer Submitted by Bristol Myers Squibb, Inc. on 09/23/2020
Nivolumab for Gastric Cancer Submitted by Bristol Myers Squibb, Inc. on 09/23/2020
Pembrolizumab for Esophageal Cancer Submitted by Merck & Co., Inc. on 11/04/2020
Fam-trastuzumab deruxtecan-nxki (Esophageal and Gastric Cancers) Submitted by Daiichi-Sankyo and Astrazeneca Pharmaceuticals on 01/21/2021
Pembrolizumab in combination with oxaliplatin and fluoropyrimidine based chemotherapy (Esophageal) Submitted by Merck & Co., Inc. on 03/23/2021
Pembrolizumab in combination with oxaliplatin and fluoropyrimidine based chemotherapy (Esophageal) Submitted by Merck & Co., Inc. on 03/31/2021
Nivolumab in combination with oxaliplatin and fluorouracil or capecitabine (Esophageal) Submitted by Bristol Myers Squibb on 04/16/2021
Nivolumab in combination with oxaliplatin and fluorouracil or capecitabine (Gastric) Submitted by Bristol Myers Squibb on 04/16/2021
Pembrolizumab, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy (Gastric) Submitted by Merck & Co., Inc. on 05/06/2021
Pembrolizumab, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy (Gastric) Submitted by Merck & Co., Inc. on 06/04/2021
Nivolumab in combination with chemotherapy (Esophageal) Submitted by Bristol Myers Squibb on 06/07/2021

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Panel

PALB2 Submitted by Myriad Genetic Laboratories, Inc. on 04/11/2017
BRCA testing Submitted by Myriad Genetic Laboratories, Inc. on 04/17/2017
Multigene Panel Testing Submitted by Myriad Genetic Laboratories, Inc. on 04/17/2017
Genetic risk evaluation Submitted by Baltimore Suburban Health on 08/03/2017
Next-generation sequencing Submitted by Illumina Inc. on 10/18/2017
Further Risk Evaluation Submitted by Myriad Genetic Laboratories, Inc. on 03/09/2018
HBOC‐related cancer Submitted by Myriad Genetic Laboratories, Inc. on 03/09/2018
RAD51D gene variations Submitted by Hines & Associates, Inc on 02/28/2019
Genetic Testing Submitted by Myriad Genetics, Inc. on 04/01/2019
Prostate Cancer Testing Criteria Submitted by Myriad Genetics, Inc. on 04/02/2019
PALB2 testing criteria Submitted by Myriad Genetics, Inc. on 04/03/2019
Personal history of ovarian carcinoma Submitted by Myriad Genetics, Inc. on 04/03/2019
Genetic Testing Submitted by Oneinforty on 04/24/2019
Genetic Testing Submitted by University of Minnesota Medical Center on 05/31/2019
BARD1- and RAD51D-associated breast cancer risk Submitted by Ambry Genetics on 10/03/2019
Multi-gene testing Submitted by Ambry Genetics on 10/03/2019
Olaparib Submitted by AstraZeneca on 10/07/2019
Breast Cancer diagnosis less than 66 years old Submitted by Myriad Genetic Laboratories, Inc. on 03/25/2020
High Penetrance Genes Submitted by Myriad Genetic Laboratories, Inc. on 03/25/2020
Prostate Cancer Testing Criteria Submitted by Myriad Genetic Laboratories, Inc. on 04/01/2020

Genetic/Familial High-Risk Assessment: Colorectal Panel

Lynch Syndrome Submitted by Myriad Genetic Laboratories, Inc. on 10/28/2019
Multi-gene testing Submitted by Myriad Genetic Laboratories, Inc. on 10/28/2019
CRC Modifications Submitted by Myriad Genetics Laboratories, Inc. on 11/05/2020

Genetic: Colorectal/Colorectal Cancer Screening Panel

Genetic risk assessment Submitted by Myriad Genetic Laboratories, Inc. on 11/10/2016
LS-specific testing Submitted by Myriad Genetic Laboratories, Inc. on 11/10/2016
Multi-gene testing Submitted by Myriad Genetic Laboratories, Inc. on 11/10/2016
MSI‐H histology Submitted by Myriad Genetic Laboratories, Inc. on 10/01/2017
Epi proColon Submitted by Epigenomics Inc. on 09/25/2018

Head and Neck Cancers Panel

Pembrolizumab Submitted by Merck & Co., Inc. on 08/05/2016
Hybrid capture based NGS Submitted by Foundation Medicine, Inc. on 08/22/2016
Pembrolizumab Submitted by Merck & Co., Inc. on 09/19/2016
Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2017
Pembrolizumab Submitted by Merck & Co., Inc. on 10/03/2017
Nivolumab Submitted by Bristol-Myers Squibb Company on 03/06/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 04/06/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 04/13/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 04/16/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 06/06/2018
Larotrectinib Submitted by Bayer HealthCare Pharmaceuticals on 10/15/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 10/22/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 12/07/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2019
Pembrolizumab Submitted by Merck & Co., Inc. on 06/26/2019
Radiation Therapy Submitted by ASTRO on 08/13/2019
Entrectinib Submitted by Genentech, Inc. on 08/15/2019
Pembrolizumab Submitted by Merck & Co., Inc. on 11/07/2019
Trastuzumab/pertuzumab Submitted by Genentech on 02/18/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Radiation Therapy Submitted by ASTRO on 05/28/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
NCCN Evidence Blocks Submitted by Merck & Co., Inc. on 06/18/2020
TMB Submitted by Foundation Medicine on 06/22/2020
TMB Submitted by Foundation Medicine on 09/15/2020

Hematopoietic Cell Transplantation Panel

Abatacept Submitted by Bristol-Myers Squibb Company on 08/01/2019
Defibrotide sodium Submitted by Jazz Pharmaceuticals on 08/02/2019
Defibrotide sodium Submitted by Jazz Pharmaceuticals on 10/22/2020
Belumosudil Submitted by Kadmon Corporation LLC on 07/21/2021

Hematopoietic Growth Factors Panel

Febrile neutropenia risk of CHOP/R-CHOP Submitted by Amgen Inc. on 05/22/2017
MGF in the palliative setting Submitted by William Stephenson, MD on 07/21/2017
Ferumoxytol Submitted by AMAG Pharmaceuticals on 04/10/2018
Epoetin alfa-epbx Submitted by Pfizer Inc. on 05/31/2018
Filgrastim-aafi Submitted by Pfizer on 08/09/2018
Pegfilgrastim-jmdb Submitted by Mylan on 10/24/2018
5-flurorouracil, oxaliplatin, leucovorin Submitted by Oncology Analytics, Inc. on 02/05/2019
Pegfilgrastim-cbqv Submitted by Coherus BioSciences on 02/11/2019
Filgrastim-sndz Submitted by Sandoz Inc. on 09/09/2019
Eflapegrastim-xnst Submitted by Spectrum Pharmaceuticals, Inc on 08/31/2020
Granulocyte Colony Stimulating Factors (G-CSF) Submitted by The University of Arizona Cancer Center on 09/17/2020
Pegfilgrastim Submitted by Coherus Biosciences on 09/17/2020
Trilaciclib Submitted by G1 Therapeutics on 09/18/2020
Ferric Derisomaltose Submitted by Pharmacosmos Therapeutics, Inc. on 09/21/2020
Trilaciclib Submitted by G1 Therapeutics on 02/12/2021

Hepatobiliary Cancers Panel

Nivolumab Submitted by Bristol-Myers Squibb Company on 09/26/2016
Nivolumab Submitted by Bristol-Myers Squibb Company on 03/06/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 06/06/2018
Ramucirumab Submitted by Eli Lilly and Company on 06/22/2018
Cabozantinib Submitted by Exelixis, Inc. on 07/13/2018
Lenvatinib Submitted by Eisai Inc. on 08/16/2018
Molecular testing Submitted by Foundation Medicine, Inc. on 08/23/2018
Lenvatinib Submitted by Eisai Inc. on 09/10/2018
Atezolizumab + Bevacizumab Submitted by Genentech, Inc. on 10/30/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 11/12/2018
Regorafenib Submitted by Bayer Healthcare Pharmaceuticals on 12/19/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 01/18/2019
Ramucirumab Submitted by Eli Lilly and Company on 05/16/2019
Larotrectinib Submitted by Bayer HealthCare on 05/28/2019
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/11/2019
Pembrolizumab Submitted by Merck & Co., Inc. on 06/14/2019
Entrectinib Submitted by Bayer HealthCare on 08/15/2019
Molecular Testing Submitted by Bayer HealthCare on 08/23/2019
Locoregional therapy Submitted by Society of Interventional Oncology on 08/26/2019
Cholangiocarcinoma Submitted by Foundation Medicine, Inc. on 09/24/2019
Atezolizumab + Bevacizumab Submitted by Genentech, Inc. on 09/27/2019
Cholangiocarcinoma Submitted by Foundation Medicine, Inc. on 10/01/2019
Nivolumab Submitted by Bristol-Myers Squibb Company on 10/02/2019
Lenvatinib Submitted by Eisai Inc. on 11/12/2019
Atezolizumab + Bevacizumab Submitted by Genentech, Inc. on 11/23/2019
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 03/11/2020
Ivosidenib Submitted by Agios Pharmaceuticals, Inc. on 03/13/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020
Pemigatinib Submitted by Incyte Corporation on 04/17/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Molecular testing Submitted by Foundation Medicine, Inc. on 05/14/2020
Lenvatinib Submitted by Eisai Inc. on 05/29/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/22/2020
Lenvatinib Submitted by Eisai Inc. on 08/12/2020
Radioembolization Submitted by Society of Interventional Oncology on 10/01/2020
Ipilimumab Submitted by Bristol Myers Squibb on 10/02/2020
Pralsetinib Submitted by Blueprint Medicines Corporation on 10/02/2020
Dabrafenib + Trametinib Submitted by Novartis Pharmaceuticals Corporation on 10/08/2020

Hodgkin Lymphoma Panel

Pembrolizumab Submitted by Merck & Co., Inc. on 03/22/2017
Vitamin D-25OH and bone mineral density testing Submitted by Aurora Health Care on 04/07/2017
Nivolumab Submitted by Bristol-Myers Squibb Company on 04/25/2017
Brentuximab vedotin Submitted by Seattle Genetics on 05/05/2017
Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2017
Pembrolizumab Submitted by Merck & Co., Inc. on 08/14/2017
Brentuximab vedotin + AVD Submitted by Seattle Genetics Inc. on 12/10/2017
Nivolumab Submitted by Bristol-Myers Squibb Company on 03/06/2018
Brentuximab vedotin Submitted by Seattle Genetics, Inc. on 06/20/2018
Brentuximab vedotin Submitted by Seattle Genetics, Inc. on 04/15/2019
Brentuximab vedotin Submitted by Seattle Genetics, Inc. on 06/26/2019
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 05/29/2020

Kidney Cancer Panel

Cabozantinib Submitted by Exelixis, Inc. on 11/14/2016
Sunitinib Submitted by Pfizer Oncology on 01/12/2017
Radiation Therapy Submitted by American Society for Radiation Oncology on 05/24/2017
Pembrolizumab Submitted by Merck & Co. on 05/31/2017
Sunitinib Submitted by Pfizer Oncology on 06/19/2017
Atezolizumab Submitted by Genentech, Inc. on 02/14/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 02/16/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 03/06/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 04/16/2018
Pazopanib Submitted by Novartis Pharmaceuticals Corporation on 05/29/2018
Atezolizumab Submitted by Genentech, Inc. on 06/25/2018
Cabozantinib Submitted by Exelixis, Inc. on 06/26/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 07/02/2018
Avelumab + Axitinib Submitted by EMD Serono, Inc. on 02/20/2019
T1a renal masses Submitted by Society of Interventional Oncology on 03/15/2019
Cabozantinib Submitted by Exelixis, Inc. on 03/21/2019
Atezolizumab Submitted by Genentech, Inc. on 05/13/2019
Bevacizumab Submitted by Amgen on 07/19/2019
Pembrolizumab Submitted by Value in Cancer Care Consortium (Vi3C) on 03/01/2020
Thermal Ablation Submitted by Society of Interventional Oncology on 03/02/2020
Lenvatinib Submitted by Eisai Inc. on 03/12/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020
Nivolumab Submitted by Bristol Myers Squibb on 09/13/2020
Lenvatinib + Pembrolizumab Submitted by Eisai Inc. on 09/24/2020
Nivolumab + Ipilimumab Submitted by Bristol Myers Squibb on 12/07/2020
Nivolumab + Cabozantinib Submitted by Bristol Myers Squibb on 01/25/2021
Nivolumab + Cabozantinib Submitted by Exelixis, Inc. on 01/25/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 02/04/2021
Nivolumab + Ipilimumab Submitted by Bristol Myers Squibb on 02/11/2021
Lenvatinib + pembrolizumab Submitted by Eisai Inc. on 02/13/2021
Lenvatinib + Everolimus Submitted by Eisai Inc. on 02/13/2021
Nivolumab + Cabozantinib Submitted by Bristol Myers Squibb on 03/04/2021
Cabozantinib + Nivolumab Submitted by Exelixis, Inc. on 03/05/2021
Cabozantinib Submitted by Exelixis, Inc. on 03/08/2021
Tivozanib Submitted by AVEO Oncology on 03/12/2021
Management of T1a renal masses Submitted by Society of Interventional Oncology on 03/31/2021
Cabozantinib Submitted by Exelixis, Inc. on 04/15/2021
Tivozanib Submitted by AVEO Oncology on 04/16/2021
Tivozanib + Nivolumab Submitted by AVEO Oncology on 04/16/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 06/07/2021

Lung Cancer Screening Panel

23-gene bronchial genomic classifier Submitted by Veracyte, Inc. on 03/12/2018

Management of Immunotherapy-Related Toxicity Panel

Cetirizine hydrochloride Submitted by TerSera Therapeutics on 11/07/2019
Guardant360 Submitted by Guardant Health, Inc. on 06/15/2020

Melanoma Panel

Ipilimumab Submitted by Bristol-Myers Squibb Company on 10/09/2016
Nivolumab/ipilimumab Submitted by Bristol-Myers Squibb Company on 04/04/2017
Pembrolizumab for MSI-H/dMMR tumors Submitted by Merck & Co. on 05/31/2017
DecisionDx-Melanoma test Submitted by Castle Biosciences Incorporated on 06/01/2017
Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/05/2017
myPath Melanoma 23-gene diagnostic expression signature Submitted by Myriad Genetic Laboratories, Inc. on 06/06/2017
CDx assay Submitted by Foundation Medicine, Inc. on 06/07/2017
Talimogene Laherparepvec in combination with ipilimumab Submitted by Amgen Inc. on 06/29/2017
Nivolumab Submitted by Bristol-Myers Squibb on 09/11/2017
Nivolumab/Ipilimumab Submitted by Bristol-Myers Squibb Company on 09/11/2017
Vemurafenib Submitted by Genentech, Inc. on 09/15/2017
Dabrafenib/trametinib Submitted by Novartis on 09/27/2017
Talimogene laherparepvec Submitted by Amgen, Inc. on 10/16/2017
Nivolumab Submitted by Bristol-Myers Squibb on 12/21/2017
Talimogene laherparepvec/ipilimumab Submitted by Amgen on 02/28/2018
Talimogene laherparepvec/pembrolizumab Submitted by Amgen on 02/28/2018
Nivolumab Submitted by Bristol-Myers Squibb on 03/06/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 04/15/2018
Next-generation based testing Submitted by Illumina Inc. on 05/18/2018
Dabrafenib/Trametinib Submitted by Novartis on 05/30/2018
Adhesive patch based non-invasive skin sampling tool Submitted by DermTech on 05/31/2018
Encorafenib (BRAF inhibitor) plus binimetinib (MEK inhibitor) Submitted by Array BioPharma Inc. on 06/20/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 11/29/2018
Larotrectinib Submitted by Bayer Healthcare Pharmaceuticals on 12/10/2018
Pigmented Lesion Assay (PLA) Submitted by DermTech on 06/27/2019
DecisionDx-Melanoma Test Submitted by Castle Biosciences, Incorporated on 06/28/2019
Principles of Molecular Testing revisions Submitted by Myriad Genetic Laboratories, Inc on 06/28/2019
Genetic testing for inherited melanoma risk Submitted by Myriad Genetic Laboratories, Inc on 06/29/2019
Pembrolizumab Submitted by Merck & Co., Inc. on 01/13/2020
Pembrolizumab dosing Submitted by Value in Cancer Care Consortium (Vi3C) on 03/01/2020
Pembrolizumab dosing Submitted by Merck & Co., Inc. on 04/29/2020
Footnote and gene mutation listings Submitted by Myriad Genetic Laboratories, Inc. on 06/09/2020
Pembrolizumab weight-based dosing Submitted by Value in Cancer Care Consortium (Vi3C) on 06/10/2020
GEP using DecisionDx-UM for Uveal Melanoma Submitted by Castle Biosciences on 06/15/2020
Pembrolizumab and low-dose ipilimumab for second- or subsequent line therapy Submitted by Merck & Co., Inc. on 06/16/2020
Pigmented lesion assay (PLA) Submitted by DermTech, Inc. on 06/16/2020
DecisionDx-Melanoma test (31-GEP) Submitted by Castle Biosciences on 06/17/2020
PLA Submitted by Dermatologic Surgery Center of Washington, LLC on 06/21/2020
Tumor mutation burden (TMB) measurement Submitted by Foundation Medicine, Inc. on 06/22/2020
Gene expression profiling (GEP) Submitted by Myriad Genetic Laboratories, Inc. on 06/22/2020
PLA Submitted by SUNY Downstate on 06/22/2020
PLA Submitted by University of Pittsburgh School of Medicine Department of Dermatology on 06/23/2020
PLA Submitted by Northwestern University Feinberg School of Medicine, Department of Dermatology on 06/23/2020
Pembrolizumab and low-dose ipilimumab for first-line Submitted by Merck & Co., Inc. on 07/21/2020
Atezolizumab in combination with cobimetinib and vemurafenib for Cutaneous Melanoma Submitted by Genentech, Inc. on 07/30/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 08/12/2020
Tumor mutation burden (TMB) measurement Submitted by Foundation Medicine, Inc. on 09/15/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 01/06/2021

Multiple Myeloma/Systemic Light Chain Amyloidosis/Waldenström's Macroglobulinemia Panel

Lenalidomide Submitted by Celgene Corporation on 08/25/2016
Carfilzomib Submitted by Amgen Inc. on 10/07/2016
Lenalidomide Submitted by Celgene Corporation on 10/20/2016
Daratumumab Submitted by Janssen Biotech, Inc. on 10/21/2016
Carfilzomib Submitted by Amgen Inc. on 01/11/2017
Carfilzomib in combination with lenalidomide and dexamethasone Submitted by Amgen Inc. on 01/26/2017
Denosumab Submitted by Amgen Inc. on 03/23/2017
Pembrolizumab Submitted by Merck & Co., Inc. on 05/02/2017
Pomalidomide Submitted by Celgene Corporation on 07/26/2017
Ibrutinib Submitted by Pharmacyclics, LLC on 08/02/2017
Pomalidomide + Dexamethasone Submitted by Celgene Corporation on 03/30/2018
Lenalidomide Submitted by Celgene Corporation on 04/12/2018
MMprofiler Submitted by SkylineDx, B.V. on 04/18/2018
Ixazomib Submitted by Takeda Oncology on 04/23/2018
Ixazomib ICd Submitted by Takeda Oncology on 04/23/2018
Ixazomib Maintenance Submitted by Takeda Oncology on 04/23/2018
Daratumumab Submitted by Janssen Biotech, Inc. on 05/09/2018
Minimal Residual Disease (MRD) analysis Submitted by Adaptive Biotechnologies on 05/10/2018
Daratumumab + Carfilzomib + Dexamethasone Submitted by Janssen Biotech, Inc. on 06/07/2018
Acalabrutinib Submitted by AstraZeneca on 06/11/2018
Ibrutinib Submitted by Pharmacyclics LLC on 06/20/2018
Ixazomib Submitted by Takeda Oncology on 12/02/2018
Daratumumab Submitted by Janssen Biotech, Inc. on 12/06/2018
Ibrutinib Submitted by Pharmacyclics LLC on 12/20/2018
Daratumumab Submitted by Janssen Biotech, Inc. on 02/12/2019
Lenalidomide Submitted by Celgene Corporation on 03/15/2019
Ixazomib Submitted by Takeda Oncology on 03/21/2019
clonoSEQ® assay Submitted by Adaptive Biotechnologies Corporation on 04/26/2019
SKY92 high risk gene expression signature Submitted by SkylineDx on 04/30/2019
SKY92 high risk gene expression signature Submitted by SkylineDx on 04/30/2019
Daratumumab Submitted by Janssen Biotech, Inc. on 05/09/2019
Pomalidomide Submitted by Celgene Corporation on 05/14/2019
Daratumumab Submitted by Janssen Biotech, Inc. on 06/07/2019
Selinexor Submitted by Karyopharm Therapeutics on 07/22/2019
Daratumumab Submitted by Janssen Scientific Affairs, LLC on 09/27/2019
Isatuximab Submitted by Sanofi Genzyme on 12/09/2019
Daratumumab Submitted by Janssen Scientific Affairs, LLC on 12/20/2019
Lenalidomide Submitted by Bristol-Myers Squibb Company on 01/16/2020
Isatuximab Submitted by Sanofi Genzyme on 03/02/2020
Dexamethasone Submitted by Acrotech Biopharma, LLC on 03/18/2020
clonoSEQ® Assay Submitted by Adaptive Biotechnologies Corporation on 03/27/2020
Ixazomib + Lenalidomide Submitted by Takeda Oncology on 03/27/2020
Ixazomib + Lenalidomide Submitted by Takeda Oncology on 03/27/2020
Ixazomib Submitted by Takeda Oncology on 03/27/2020
Daratumumab Submitted by Janssen Scientific Affairs, LLC on 05/12/2020
Daratumumab and Hyaluronidase-fihj Submitted by Janssen Scientific Affairs, LLC on 06/16/2020
Zanubrutinib Submitted by BeiGene, Ltd. on 07/31/2020
Belantamab mafodotin-blmf Submitted by GlaxoSmithKline on 08/05/2020
Carfilzomib Submitted by Amgen Inc. on 08/21/2020
Selinexor Submitted by Karyopharm Therapeutics on 11/12/2020
Ibrutinib Submitted by Pharmacyclics LLC on 12/07/2020
Daratumumab and Hyaluronidase-fihj Submitted by Janssen Scientific Affairs, LLC on 02/01/2021
Melphalan flufenamide Submitted by Oncopeptides, Inc. on 03/01/2021
Idecabtagene Vicleucel Submitted by Bristol Myers Squibb on 03/26/2021
Isatuximab Submitted by Sanofi Genzyme on 03/31/2021

Myelodysplastic Syndromes Panel

Next-generation sequencing Submitted by Illumina Inc. on 11/30/2017
Patient evaluation Submitted by Foundation Medicine, Inc. on 03/26/2018
Luspatercept-aamt Submitted by Bristol-Myers Squibb Company on 01/09/2020
Luspatercept-aamt Submitted by Bristol Myers Squibb on 04/10/2020
Decitabine and Cedazuridine Submitted by Taiho Oncology, Inc. on 07/10/2020

Myeloproliferative Neoplasms Panel

Fedratinib Submitted by Celgene Corporation on 06/27/2019
Fedratinib Submitted by Celgene Corporation on 08/16/2019
Comprehensive genomic profiling Submitted by Foundation Medicine, Inc. on 07/16/2020
Avapritinib Submitted by Blueprint Medicines Corporation on 06/17/2021

Neuroendocrine Tumors Panel

Telotristat ethyl Submitted by Lexicon Pharmaceuticals, Inc. on 03/09/2017
Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2017
Everolimus + Octreotide (LAR) Submitted by Novartis Pharmaceutical Corporation on 07/07/2017
Lutetium Lu 177 dotatate Submitted by Advanced Accelerator Applications, a Novartis Company on 01/30/2018
HSA iobenguane I 131 Submitted by Progenics Pharmaceuticals, Inc. on 07/10/2018
HSA iobenguane I 131 Submitted by Progenics Pharmaceuticals Inc. on 09/07/2018
HSA iobenguane I 131 Submitted by Progenics Pharmaceuticals Inc. on 09/11/2018
Avelumab Submitted by EMD Serono, Inc. on 03/05/2019
Telotristat ethyl Submitted by Lexicon Pharmaceuticals, Inc. on 05/06/2019
Entrectinib Submitted by Genentech, Inc. on 08/15/2019
Copper Cu 64 dotatate Submitted by Curium on 10/07/2019
Liver-Directed Therapy Submitted by Society of Interventional Oncology on 10/15/2019
Nivolumab/Ipilimumab Submitted by Bristol-Myers Squibb Company on 04/16/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
SSR PET tracer options Submitted by Curium on 09/03/2020
Pralsetinib Submitted by Blueprint Medicines Corporation on 09/10/2020
TMB and pembrolizumab Submitted by Foundation Medicine, Inc. on 09/18/2020
Liver Directed Therapy Submitted by Society of Interventional Oncology on 10/08/2020
Principles of Hormone Control Submitted by TerSera Therapeutics on 10/27/2020

Non-Hodgkin`s Lymphomas Panel

Obinituzumab Submitted by Genentech, Inc. on 12/05/2016
Ibrutinib + Rituximab Submitted by Pharmacyclics on 12/07/2016
Ibrutinib Submitted by Pharmacyclics on 01/19/2017

Non-Melanoma Skin Cancer Panel

Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. on 06/15/2018
Pembrolizumab for Squamous Cell Skin Cancer Submitted by Merck & Co., Inc. on 09/28/2019
Pembrolizumab Submitted by Merck & Co., Inc. on 09/29/2019
Pembrolizumab for Basal Cell Skin Cancer Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab for Merkel Cell Carcinoma Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab for Squamous Cell Skin Cancer Submitted by Merck & Co., Inc. on 03/20/2020
Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. on 03/26/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/25/2020
Pembrolizumab for Squamous Cell Skin Cancer Submitted by Merck & Co., Inc. on 06/25/2020
Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. on 07/08/2020
Pembrolizumab for Squamous Cell Skin Cancer Submitted by Merck & Co., Inc. on 09/14/2020
Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. on 02/10/2021

Non-Small Cell Lung Cancer/Malignant Pleural Mesothelioma/Thymomas and Thymic Carcinomas Panel

Dabrafenib and Trametinib Submitted by Novartis Pharmaceuticals Corporation on 08/29/2016
Pembrolizumab Submitted by Merck & Co., Inc. on 10/11/2016
Pembrolizumab Submitted by Merck & Co., Inc. on 10/12/2016
Atezolizumab Submitted by Genentech, Inc. on 10/18/2016
Ceritinib Submitted by Novartis Pharmaceuticals Corporation on 12/05/2016
Atezolizumab Submitted by Genentech, Inc. on 12/12/2016
Osimertinib Submitted by AstraZeneca on 12/14/2016
Ceritinib Submitted by Novartis Pharmaceuticals Corporation on 03/08/2017
Pembrolizumab Submitted by Merck & Co., Inc. on 04/25/2017
Durvalumab Submitted by AstraZeneca on 05/02/2017
Brigatinib Submitted by Takeda Oncology on 05/09/2017
Molecular profiling Submitted by Foundation Medicine, Inc. on 05/26/2017
Pembrolizumab Submitted by Merck & Co. on 05/31/2017
Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2017
Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2017
Ceritinib Submitted by Novartis Pharmaceuticals Corporation on 06/01/2017
Alectinib Submitted by Genentech, Inc. on 06/06/2017
Nivolumab Submitted by Bristol-Myers Squibb Company on 06/06/2017
Pembrolizumab Submitted by Merck & Co., Inc. on 06/08/2017
Osimertinib Submitted by AstraZeneca on 09/09/2017
Durvalumab Submitted by AstraZeneca on 09/09/2017
Alectinib Submitted by Genentech, Inc. on 11/06/2017
Osimertinib Submitted by AstraZeneca on 11/18/2017
Ramucirumab Submitted by Eli Lilly and Company on 11/20/2017
Guardant360 Submitted by Guardant Health, Inc. on 12/06/2017
Atezolizumab Submitted by Genentech, Inc. on 12/07/2017
Afatinib Submitted by Boehringer-Ingelheim Pharmaceuticals, Inc. on 01/23/2018
Afatinib Submitted by Boehringer-Ingelheim Pharmaceuticals, Inc. on 03/06/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 03/06/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 03/08/2018
Next-generation sequencing Submitted by Illumina Inc. on 04/11/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 04/16/2018
Ipilimumab Submitted by Bristol-Myers Squibb Company on 04/16/2018
Osimertinib Submitted by AstraZeneca on 04/18/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 05/02/2018
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 05/04/2018
Gefitinib Submitted by AstraZeneca on 05/14/2018
Tumor Mutational Burden Submitted by Foundation Medicine, Inc. on 05/25/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 06/03/2018
Durvalumab Submitted by AstraZeneca on 06/03/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 06/03/2018
Atezolizumab and Alectinib Submitted by Genentech, Inc. on 06/04/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 06/04/2018
Osimertinib Submitted by AstraZeneca on 06/06/2018
Avelumab Submitted by EMD Serono, Inc. on 06/11/2018
Dabrafenib and Trametinib Submitted by Novartis Pharmaceuticals Corporation on 06/15/2018
Afatinib Submitted by Boehringer-Ingelheim Pharmaceuticals, Inc. on 07/24/2018
Guardant360 Submitted by Guardant Health, Inc. on 09/23/2018
Guardant360 Submitted by Guardant Health, Inc., on 09/23/2018
Atezolizumab Submitted by Genentech, Inc. on 09/24/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 09/27/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 09/28/2018
Dacomitinib Submitted by Pfizer Inc on 10/01/2018
Brigatinib Submitted by Takeda Oncology on 10/02/2018
Brigatinib Submitted by Takeda Oncology on 10/02/2018
Afatinib Addendum Submitted by Boehringer Ingelheim Pharmaceuticals Inc. on 10/11/2018
Atezolizumab Submitted by Genentech, Inc. on 10/23/2018
Durvalumab Submitted by AstraZeneca Pharmaceuticals LP/Medical Affairs on 10/25/2018
Nivolumab Submitted by Bristol-Myers Squibb on 10/26/2018
Lorlatinib Submitted by Pfizer Inc. on 11/02/2018
Larotrectinib Submitted by Bayer Healthcare Pharmaceuticals on 12/10/2018
Osimertinib Submitted by AstraZeneca on 01/17/2019
Nivolumab Submitted by Bristol-Myers Squibb Company on 02/13/2019
Pembrolizumab Submitted by Merck & Co., Inc. on 03/11/2019
Pembrolizumab Submitted by Merck & Co., Inc. on 04/12/2019
Durvalumab Submitted by AstraZeneca on 06/03/2019
Brigatinib Submitted by Takeda Oncology on 06/06/2019
Brigatinib Post Crizotinib Submitted by Takeda Oncology on 06/10/2019
Image-Guided Thermal Ablation (IGTA) Submitted by Society of Interventional Oncology on 06/21/2019
Bevacizumab-awwb Submitted by Amgen on 07/19/2019
Liquid Biopsy Submitted by AstraZeneca on 08/07/2019
Entrectinib Submitted by Genentech, Inc. on 08/15/2019
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 09/28/2019
Atezolizumab Submitted by Genentech, Inc. on 09/30/2019
Ramucirumab Submitted by Eli Lilly and Company on 10/29/2019
Atezolizumab Submitted by Genentech, Inc. on 12/03/2019
Guardant360 Submitted by Guardant Health, Inc. on 01/22/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020
Selpercatinib Submitted by Eli Lilly and Company on 03/27/2020
Guardant360 Submitted by Guardant Health, Inc. on 03/27/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/13/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Capmatinib Submitted by Novartis Pharmaceuticals Corporation on 05/06/2020
Selpercatinib Submitted by Eli Lilly and Company on 05/08/2020
Durvalumab Submitted by AstraZeneca on 05/14/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 05/15/2020
Atezolizumab Submitted by Genentech, Inc. on 05/20/2020
Nivolumab + Ipilimumab Submitted by Bristol Myers Squibb Company on 05/26/2020
Brigatinib Submitted by Takeda Oncology on 05/26/2020
Nivolumab + Ipilimumab Submitted by Bristol Myers Squibb Company on 05/29/2020
Osimertinib Submitted by AstraZeneca on 05/31/2020
Pembrolizumab Submitted by Value in Cancer Care Consortium (Vi3C) on 06/10/2020
T-DXd Submitted by Daiichi Sankyo, Inc. on 06/15/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/22/2020
Key Recommendations Submitted by American Society for Radiation Oncology on 06/23/2020
Lenvatinib Submitted by Eisai Inc. on 06/23/2020
Comprehensive genomic profiling Submitted by Foundation Medicine, Inc. on 06/30/2020
Image-Guided Thermal Ablation (IGTA) Submitted by Society of Interventional Oncology on 07/01/2020
Guardant360 Submitted by Guardant Health, Inc. on 07/02/2020
Tumor Treating Fields Submitted by Novocure Inc. on 07/03/2020
Bevacizumab Submitted by Genentech, Inc. on 07/06/2020
Brigatinib Submitted by Takeda Oncology on 07/07/2020
Capmatinib Submitted by Novartis Pharmaceuticals Corporation on 07/08/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 07/13/2020
Nivolumab + Ipilimumab Submitted by Bristol Myers Squibb on 08/08/2020
Pralsetinib Submitted by Blueprint Medicines Corporation on 09/08/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 09/15/2020
Osimertinib Submitted by AstraZeneca on 09/19/2020
Selpercatinib Submitted by Eli Lilly and Company on 09/21/2020
Atezolizumab Submitted by Genentech, Inc. on 10/01/2020
Nivolumab + Ipilimumab Submitted by Bristol Myers Squibb on 10/02/2020
Capmatinib Submitted by Novartis Pharmaceuticals Corporation on 11/04/2020
Lorlatinib Submitted by Pfizer Inc. on 11/19/2020
Durvalumab Submitted by AstraZeneca Pharmaceuticals LP on 11/20/2020
Osimertinib Submitted by AstraZeneca on 12/21/2020
Nivolumab + Ipilimumab Submitted by Bristol Myers Squibb on 01/18/2021
Nivolumab + Ipilimumab Submitted by Bristol Myers Squibb on 01/21/2021
Tepotinib Submitted by EMD Serono, Inc. on 02/04/2021
Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. on 02/16/2021
Sotorasib Submitted by Amgen, Inc. on 04/22/2021
Amivantamab-vmjw Submitted by Janssen Biotech, Inc. on 05/24/2021

Occult Primary Panel

Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2017
Vitrakvi Submitted by Bayer Healthcare Pharmaceuticals on 12/10/2018
Entrectinib Submitted by Genentech, Inc. on 08/15/2019
Pembrolizumab Submitted by Merck & Co., Inc. on 03/11/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/19/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 09/15/2020

Older Adult Oncology Panel

Cetirizine hydrochloride Submitted by TerSera Therapeutics on 09/11/2020
Guardant360 CDx Submitted by Guardant Health on 09/30/2020
Cetirizine hydrochloride Submitted by TerSera Therapeutics on 03/05/2021

Ovarian Cancer Panel

Olaparib Submitted by AztraZeneca on 09/13/2016
Trabectedin/docetaxel Submitted by Janssen Biotech on 09/30/2016
Multivariate index assay test OVA1 Submitted by Vermillion/ASPiRA Labs on 10/18/2016
Bevacizumab Submitted by Genentech on 12/07/2016
Rucaparib Submitted by Clovis Oncology on 12/20/2016
Niraparib Submitted by Tesaro on 04/11/2017
Pembrolizumab Submitted by Merck & Co. on 05/31/2017
Olaparib Submitted by AstraZeneca on 08/17/2017
Rucaparib Submitted by Clovis Oncology, Inc. on 09/19/2017
Next-generation sequencing (NGS) Submitted by Illumina Inc. on 10/09/2017
Homologous recombination deficiency (HRD) status Submitted by Myriad Genetic Laboratories, Inc. on 10/18/2017
Avelumab Submitted by EMD Serono, Inc. and Pfizer Inc. on 10/20/2017
OVA1/Multivariate Index Assay Submitted by Vermillion/AsPIRA Laboratories on 10/24/2017
Comprehensive genomic profiling (CGP) Submitted by Foundation Medicine, Inc. on 10/25/2017
Bevacizumab Submitted by Genentech, Inc. on 10/31/2017
PARP inhibitors Submitted by Tesaro, Inc. on 01/22/2018
Bevacizumab Submitted by Genentech, Inc. on 06/13/2018
Niraparib Submitted by Tesaro Inc. on 06/25/2018
PARP inhibitor maintenance Submitted by Tesaro Inc. on 10/10/2018
Niraparib Submitted by Tesaro Inc. on 10/12/2018
Olaparib Submitted by AstraZeneca on 10/22/2018
Olaparib Submitted by AstraZeneca on 06/03/2019
Olaparib Submitted by AstraZeneca on 07/02/2019
Paxman Scalp Cooling System Submitted by Paxman Coolers Limited on 07/26/2019
Entrectinib Submitted by Genentech, Inc. on 08/15/2019
OVA1/Multivariate Index Assay Submitted by Vermillion, Inc. on 09/18/2019
Bevacizumab-awwb Submitted by Tejas Patel, PharmD, BCOP United Healthcare on 09/26/2019
Nirabarib Submitted by GSK on 09/30/2019
Olaparib Submitted by AstraZeneca on 10/01/2019
Molecular testing Submitted by Foundation Medicine, Inc. on 10/02/2019
Trabectedin Submitted by Janssen Scientific Affairs on 02/04/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Olaparib Submitted by Clovis Oncology on 05/15/2020
Olaparib Submitted by AstraZeneca on 05/15/2020
Niraparib Submitted by GSK on 05/19/2020
Nivolumab Submitted by Bristol Myers Squibb on 06/04/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
myChoice CDx Submitted by Myriad Genetics Laboratories on 09/08/2020
OVA1 Multivariate Index Assay Submitted by ASPiRA Women’s Health on 09/10/2020
Guardant360 Submitted by Guardant Health on 09/11/2020
Lurbinectedin Submitted by Jazz Pharmaceuticals on 09/16/2020
TMB Submitted by Foundation Medicine, Inc. on 09/18/2020
CDx genomic profiling test Submitted by Foundation Medicine, Inc. on 11/06/2020

Palliative Care Panel

Interventional Radiologist (IR) consultation Submitted by Society of Interventional Oncology on 07/13/2020

Pancreatic Adenocarcinoma Panel

Irreversible electroporation Submitted by AngioDynamics on 08/10/2016
Genetic testing Submitted by Myriad Genetic Laboratories, Inc. on 08/11/2016
Pembrolizumab Submitted by Merck & Co. on 05/31/2017
Comprehensive Genomic Profiling Submitted by Foundation Medicine, Inc. on 07/03/2018
Olaparib Submitted by AstraZeneca on 06/02/2019
Olaparib Submitted by AstraZeneca on 06/02/2019
Microsatellite Instability (MSI) assays Submitted by Promega Corporation on 06/25/2019
Entrectinib Submitted by Genentech, Inc. on 08/15/2019
Evidence Blocks Submitted by United Healthcare on 02/24/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Germline testing Submitted by Myriad Genetics Laboratories, Inc. on 06/08/2020
Genomic profiling Submitted by Foundation Medicine, Inc. on 06/12/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
Gemcitabine/albumin-bound paclitaxel/cisplatin Submitted by Dr. Dan Laheru on 06/18/2020
TMB Submitted by Foundation Medicine, Inc. on 06/22/2020
TMB Submitted by Foundation Medicine, Inc. on 09/15/2020

Pediatric Acute Lymphoblastic Leukemia Panel

Blinatumomab Submitted by Amgen, Inc. on 02/11/2020
ClonoSEQ® Assay Submitted by Adaptive Biotechnologies Corporation on 05/22/2020
Asparaginase erwinia chrysanthemi (recombinant) Submitted by Jazz Pharmaceuticals on 07/02/2021

Pediatric Hodgkin Lymphoma Panel

Pembrolizumab Submitted by Merck & Co., Inc. on 10/15/2020

Prevention and Treatment of Cancer-Related Infections Panel

Isavuconazonium sulfate Submitted by Astellas Pharma Global Development, Inc on 08/31/2016
Oritavancin Submitted by Global Health Science on 09/30/2016
Meropenem and Vaborbactam Submitted by Melinta Therapeutics, Inc. on 10/01/2018
Bezlotoxumab Submitted by Merck & Co. on 05/29/2019
Temp Traq Submitted by Blue Spark Technologies on 06/26/2019

Prostate Cancer Early Detection Panel

Family History Submitted by Myriad Genetic Laboratories, Inc. on 09/19/2016
SelectMDx Submitted by MDxHealth on 09/20/2016
3-gene expression assay Submitted by Exosome Diagnostics, Inc. on 01/04/2017
Family History Submitted by Myriad Genetic Laboratories, Inc. on 08/02/2017
3-gene expression assay Submitted by Exosome Diagnostics, Inc on 01/05/2018
EPI biomarker Submitted by Exosome Diagnostics, Inc on 04/23/2018
3-gene expression assay Submitted by Exosome Diagnostics, Inc on 08/13/2018
EPI test Submitted by Exosome Diagnostics, Inc on 09/20/2018
SelectMDx Submitted by MDxHealth on 10/02/2018
SelectMDx Submitted by MDxHealth on 06/03/2019
Germline Genetic Testing Submitted by Myriad Genetic Laboratories, Inc. on 09/18/2020
miR Scientific Sentinel Prostate Cancer Test Platform Submitted by Columbia University Medical Center on 09/23/2020
miR Scientific Sentinel™ Prostate Cancer Test Platform Submitted by miR Scientific on 09/29/2020

Prostate Cancer Panel

Uridine triacetate Submitted by Wellstat Therapeutics on 08/16/2016
Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2017
Active Surveillance Submitted by Prostate Cancer Patient Education and Advocacy Organizations on 05/31/2017
Tissue-based molecular assay Submitted by GenomeDx Biosciences Inc. on 06/01/2017
Tumor-based molecular assays Submitted by Myriad Genetic Laboratories, Inc. on 06/07/2017
Abiraterone acetate Submitted by Janssen Scientific Affairs, LLC on 06/08/2017
Abiraterone Acetate Submitted by Kansas City Urology Care on 12/07/2017
Apalutamide Submitted by Janssen Scientific Affairs, LLC on 02/15/2018
Enzalutamide Submitted by Astellas Pharma Inc. on 03/15/2018
Apalutamide Submitted by Janssen Scientific Affairs, LLC on 05/23/2018
Genomic classifier Submitted by GenomeDx Biosciences Inc. on 06/01/2018
Fluciclovine Submitted by Blue Earth Diagnostics, Inc. on 06/06/2018
AR-V7 Submitted by Epic Sciences, Inc. on 06/07/2018
Prolaris Submitted by Myriad Genetic Laboratories, Inc. on 06/07/2018
Prolaris Post‐RP Submitted by Myriad Genetic Laboratories, Inc. on 06/07/2018
Denosumab and Zolendronic Acid Submitted by Prostate Health Education Network, Inc. on 06/20/2018
Enzalutamide Submitted by Astellas Pharma on 07/13/2018
GnRH antagonist degarelix Submitted by Ferring Pharmaceuticals on 10/11/2018
Abiraterone Acetate Submitted by Value in Cancer Care Consortium (ViC3) on 10/14/2018
Sipuleucel-T Submitted by Dendreon Pharmaceuticals LLC on 02/19/2019
Abiraterone Acetate Submitted by Janssen Scientific Affairs, LLC on 03/15/2019
Abiraterone Acetate Submitted by Janssen Scientific Affairs, LLC on 04/09/2019
Tumor Tissue-Based Molecular Assay Submitted by Decipher Biosciences Inc. on 06/01/2019
Apalutamide Submitted by Janssen Scientific Affairs, LLC on 06/04/2019
Molecular and biomarker analysis of tumor Submitted by Myriad Genetic Laboratories, Inc. on 06/04/2019
Genetic Testing in Active Surveillance Submitted by Myriad Genetic Laboratories, Inc. on 06/04/2019
Genetic Testing and Risk Stratification Submitted by Myriad Genetic Laboratories, Inc. on 06/04/2019
PCR-based Microsatellite Instability (MSI) assays Submitted by Promega Corporation on 06/06/2019
Abiraterone Acetate Submitted by Janssen Scientific Affairs, LLC on 06/11/2019
Enzalutamide Submitted by Astellas Pharma Global Development, Inc. on 07/29/2019
Olaparib Submitted by AstraZeneca on 09/30/2019
Cabazitaxel Submitted by Sanofi on 10/08/2019
Atezolizumab Submitted by Genentech, Inc. on 11/27/2019
Pembrolizumab Submitted by Merck & Co., Inc. on 03/11/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020
Cabazitaxel Submitted by Sanofi on 03/23/2020
Guardant360 Submitted by Guardant Health, Inc. on 04/22/2020
Molecular/Biomarker Analysis Submitted by Myriad Genetic Laboratories, Inc. on 04/23/2020
Genetic Testing and Risk Stratification Submitted by Myriad Genetic Laboratories, Inc. on 04/23/2020
Genomic profiling Submitted by Foundation Medicine, Inc. on 04/29/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Cabazitaxel Submitted by Sanofi on 05/04/2020
Darolutamide Submitted by Bayer Healthcare Pharmaceuticals on 05/11/2020
Rucaparib Submitted by Clovis Oncology, Inc. on 05/15/2020
Rucaparib Submitted by Clovis Oncology, Inc. on 05/15/2020
Relugolix Submitted by Myovant Sciences, Inc. on 12/23/2020

Small Cell Lung Cancer Panel

Pembrolizumab Submitted by Merck & Co., Inc. on 06/07/2018
Atezolizumab Submitted by Genentech, Inc. on 09/25/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 04/11/2019
Entrectinib Submitted by Genentech, Inc. on 08/15/2019
Durvalumab Submitted by AstraZeneca Pharmaceuticals on 09/19/2019
Nivolumab Submitted by Bristol-Myers Squibb Company on 12/04/2019
Atezolizumab Submitted by Genentech, Inc. on 12/23/2019
Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020
Lurbinectedin Submitted by Jazz Pharmaceuticals on 04/29/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Lurbinectedin Submitted by Jazz Pharmaceuticals on 06/15/2020
Nivolumab Submitted by Bristol-Myers Squibb Company on 12/29/2020
Trilaciclib Submitted by G1 Therapeutics on 02/12/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 03/31/2021

Soft Tissue Sarcoma Panel

Diagnostic Algortihm Submitted by The Life Raft Group on 05/21/2019
ENLIVEN, pexidartinib Submitted by Daiichi-Sankyo on 08/05/2019
Entrectinib Submitted by Genentech, Inc. on 08/16/2019
Avapritinib Submitted by Blueprint Medicines Corporation on 01/07/2020
Avapritinib Submitted by Blueprint Medicines Corporation on 01/09/2020
Tazemetostat Submitted by Epizyme Inc. on 01/23/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 03/11/2020
Treatment Algorithm Submitted by The Desmoid Tumor Research Foundation on 03/17/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Ripretinib Submitted by Deciphera Pharmaceuticals on 05/18/2020
Footnotes Submitted by Society of Interventional Oncology on 06/08/2020
Cabozantinib Submitted by Exelixis, Inc. on 06/10/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
Comprehensive genomic profiling (CGP) Submitted by Foundation Medicine, Inc. on 06/17/2020
Ripretinib Submitted by Deciphera Pharmaceuticals on 06/19/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/23/2020
Ripretinib Submitted by Deciphera Pharmaceuticals on 08/17/2020

Survivorship Panel

Genetic risk assessment Submitted by Myriad Genetic Laboratories, Inc. on 10/10/2016
Naloxegol Submitted by AstraZeneca/Medical Affairs on 10/04/2017
Lymphedema symptom assessment Submitted by Vanderbilt University School of Nursing on 10/31/2018
LGBTQ Resources Submitted by Tanya Fischer on 04/18/2019
Genetic risk assessment and testing Submitted by Myriad Genetic Laboratories on 10/29/2019

T-Cell/Primary Cutaneous Lymphomas Panel

Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2017
Brentuximab vedotin Submitted by Seattle Genetics, Inc. on 05/30/2017
Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2017
Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2017
Brentuximab vedotin Submitted by Seattle Genetics, Inc. on 06/07/2017
Ibrutinib Submitted by Pharmacyclics LLC on 09/29/2017
Defibrotide Submitted by Jazz Pharmaceuticals on 11/17/2017
Next-generation sequencing (NGS) Submitted by Illumina Inc. on 05/07/2018
Next generation sequence based analysis Submitted by Adaptive Biotechnologies on 05/18/2018
Mogamulizumab Submitted by Kyowa Kirin, Inc. on 07/30/2018
Brentuximab vedotin Submitted by Seattle Genetics, Inc. on 11/21/2018
Duvelisib Submitted by Verastem, Inc. on 05/17/2019
Duvelisib + Romidepsin Submitted by Verastem, Inc. on 05/17/2019
Next-generation sequencing (NGS) Submitted by Adaptive Biotechnologies Corporation on 06/28/2019
Pembrolizumab Submitted by Merck & Co., Inc. on 02/03/2020
Duvelisib Submitted by Verastem, Inc. on 06/11/2020
Leucovorin Submitted by Acrotech Biopharma, LLC on 06/12/2020
ENKTL Submitted by Sun Yat-sen University Cancer Center on 06/14/2020
clonoSEQ® Assay Submitted by Adaptive Biotechnologies Corporation on 06/19/2020

Testicular Cancer Panel

Pembrolizumab Submitted by Merck & Co. on 05/31/2017
BEP x 3 Submitted by Indiana University Simon Cancer Center on 03/05/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020

Thyroid Carcinoma Panel

Lenvatinib Submitted by Eisai Inc. on 10/27/2017
Dabrafenib + Trametinib Submitted by Novartis Pharmaceuticals Corporation on 01/09/2018
Thyrotropin alfa Submitted by Sanofi US on 08/31/2018
Larotrectinib Submitted by Bayer Healthcare Pharmaceuticals on 10/15/2018
Thyrotropin alfa Submitted by Sanofi US on 04/22/2019
Entrectinib Submitted by Genentech, Inc. on 08/16/2019
Selpercatinib Submitted by Eli Lilly and Company on 05/08/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/29/2020
Pralsetinib Submitted by Blueprint Medicines Corporation on 12/01/2020